HIV drug resistance: brief report 2024
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment. In this report, WHO documents
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment. In this report, WHO documents
<p>Order of the High Court of Kerala regarding exorbitant pricing of life saving patented medicines.</p> <p>The High Court wanted the opinion of the government of India on whether the breast cancer medicines
The Department of Pharmaceuticals (DoP) has come out with a draft National Pharmaceuticals Policy (NPP) 2023 emphasising on a holistic policy approach to address the challenges faced by Indian pharmaceutical
<p>Order of the Supreme Court of India in the matter of All India Drug Action Network & Others Vs Union of India Ministry of Health & Others dated 13/09/2023. Additional Solicitor General informed
<p>The bench of Justice Satish Chander Sharma and Justice Sanjeev Narula of the Delhi High Court, September 1, 2023 directed Union of India to furnish the reasons as to why the drug ‘Nimesulide’
The Department of Pharmaceuticals (DoP) has notified the National Policy on Research & Development and Innovation in the Pharma-Med Tech Sector in India with reforms in terms of regulatory framework and
The Global Action Plan on HIV drug resistance 2017–2021 provided a comprehensive framework for global and country action and outlined a package of interventions and resources to guide the collective response
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic
Trafficked medical products kill almost half a million sub-Saharan Africans every year, and action is needed to stem the flow, the United Nations Office on Drugs and Crime (UNODC) states in its new threat
The WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) was launched in 2015 to foster AMR surveillance and inform strategies to contain AMR. The system started with surveillance of